Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints-Reference-Cited by-同舟云学术

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints

Published:2014-06-23 Issue:14 Volume:13 Page:2172-2191
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Beeharry Neil,Banina Eugenia,Hittle James,Skobeleva Natalia,Khazak Vladimir,Deacon Sean,Andrake Mark,Egleston Brian L,Peterson Jeffrey R,Astsaturov Igor,Yen Timothy J

Publisher

Informa UK Limited

Subject

Cell Biology,Developmental Biology,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.4161/cc.29214

Reference45 articles.

1. Mechanisms of Mitotic Cell Death Induced by Chemotherapy-Mediated G2Checkpoint Abrogation

2. ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1

3. Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe

4. Role of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine

5. Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Few-Shot Drug Synergy Prediction With a Prior-Guided Hypernetwork Architecture;IEEE Transactions on Pattern Analysis and Machine Intelligence;2023-08

2. Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders;ACS Omega;2023-06-02

3. Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects;Journal of Nanobiotechnology;2023-03-21

4. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target;Journal of Hematology & Oncology;2020-09-21

5. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia;Journal of Hematology & Oncology;2018-08-01